Search - tctmd.com

Displaying 1 - 20 of 66

Sort: Relevancy | Date

Heart Failure Care Has a Pipeline Problem: What’s the Fix?

News Features

Heart Failure Care Has a Pipeline Problem: What’s the Fix?

December 20, 2022

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

Query Use of Nontraditional Therapies for HF at Every Visit: AHA Statement

News Daily News

Query Use of Nontraditional Therapies for HF at Every Visit: AHA Statement

December 09, 2022

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

Sequencing HF Meds? Most Doctors Stick to Old Habits, Survey Says

News Daily News

Sequencing HF Meds? Most Doctors Stick to Old Habits, Survey Says

December 08, 2022

STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends

News Conference News AHA 2022

STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends

November 07, 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

November 06, 2022

IRONMAN Misses but Lends Support to IV Iron Repletion in HF

News Conference News AHA 2022

IRONMAN Misses but Lends Support to IV Iron Repletion in HF

November 05, 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

News Conference News AHA 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

November 05, 2022

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

News Conference News AHA 2022

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

Yael L. Maxwell

November 01, 2022

STRONG-HF: Fast Optimal GDMT Cuts Deaths, Hospitalizations in Acute HF

News Daily News

STRONG-HF: Fast Optimal GDMT Cuts Deaths, Hospitalizations in Acute HF

October 17, 2022

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

News Daily News

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

October 12, 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

News Conference News HFSA 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

October 07, 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

October 07, 2022

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

News Conference News HFSA 2022

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

October 04, 2022

Concerning or Reassuring? Long After COVID-19, CMR Still Yields Clues

News Daily News

Concerning or Reassuring? Long After COVID-19, CMR Still Yields Clues

Michael O'Riordan

October 03, 2022

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

News Daily News

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Michael O'Riordan

September 09, 2022

Older Adults See Rebound in Rates of HF-Related Death: CDC Data

News Daily News

Older Adults See Rebound in Rates of HF-Related Death: CDC Data

September 09, 2022

Sacubitril/Valsartan Versus Ramipril for Patients with Acute Myocardial Infarction: Win-ratio Analysis of the PARADISE-MI Trial

Presentation ESC 2022

Sacubitril/Valsartan Versus Ramipril for Patients with Acute Myocardial Infarction: Win-ratio Analysis of the PARADISE-MI Trial

Presenter: Otavio Berwanger

August 29, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.